Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection

Maria Friberg, Ronald Jennings, Marwan Alsarraj, Sophie Dessureault, Alan Cantor, Martine Extermann, Andrew L. Mellor, David H. Munn, Scott J. Antonia

Research output: Contribution to journalArticle

269 Citations (Scopus)

Abstract

The priming of an appropriate anti-tumor T cell response rarely results in the rejection of established tumors. The characteristics of tumors that allow them to evade a T cell-mediated rejection are unknown for many tumors. We report on evidence that the expression of the immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO) by mononuclear cells that invade tumors and tumor-draining lymph nodes, is I mechanism that may account for this observation. Lewis lung carcinoma (LLC) cells stimulated a more robust allogeneic T cell response in vitro in the presence of a competitive inhibitor of IDO, I-methyl tryptophan. When administered in vivo this inhibitor also resulted in delayed LLC tumor growth in syngeneic mice. Our study provides evidence for a novel mechanism whereby tumors evade rejection by the immune system, and suggests the possibility that inhibiting IDO may be developed as an anti-cancer immunotherapeutic strategy.

Original languageEnglish (US)
Pages (from-to)151-155
Number of pages5
JournalInternational Journal of Cancer
Volume101
Issue number2
DOIs
StatePublished - Sep 10 2002

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
T-Lymphocytes
Neoplasms
Lewis Lung Carcinoma
Immunosuppressive Agents
Immune System
Lymph Nodes

Keywords

  • Indoleamine 2,3-dioxygenase
  • T cell
  • Tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., ... Antonia, S. J. (2002). Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer, 101(2), 151-155. https://doi.org/10.1002/ijc.10645

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. / Friberg, Maria; Jennings, Ronald; Alsarraj, Marwan; Dessureault, Sophie; Cantor, Alan; Extermann, Martine; Mellor, Andrew L.; Munn, David H.; Antonia, Scott J.

In: International Journal of Cancer, Vol. 101, No. 2, 10.09.2002, p. 151-155.

Research output: Contribution to journalArticle

Friberg, M, Jennings, R, Alsarraj, M, Dessureault, S, Cantor, A, Extermann, M, Mellor, AL, Munn, DH & Antonia, SJ 2002, 'Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection', International Journal of Cancer, vol. 101, no. 2, pp. 151-155. https://doi.org/10.1002/ijc.10645
Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer. 2002 Sep 10;101(2):151-155. https://doi.org/10.1002/ijc.10645
Friberg, Maria ; Jennings, Ronald ; Alsarraj, Marwan ; Dessureault, Sophie ; Cantor, Alan ; Extermann, Martine ; Mellor, Andrew L. ; Munn, David H. ; Antonia, Scott J. / Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. In: International Journal of Cancer. 2002 ; Vol. 101, No. 2. pp. 151-155.
@article{36590aa67c124a3bb0148faea1088387,
title = "Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection",
abstract = "The priming of an appropriate anti-tumor T cell response rarely results in the rejection of established tumors. The characteristics of tumors that allow them to evade a T cell-mediated rejection are unknown for many tumors. We report on evidence that the expression of the immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO) by mononuclear cells that invade tumors and tumor-draining lymph nodes, is I mechanism that may account for this observation. Lewis lung carcinoma (LLC) cells stimulated a more robust allogeneic T cell response in vitro in the presence of a competitive inhibitor of IDO, I-methyl tryptophan. When administered in vivo this inhibitor also resulted in delayed LLC tumor growth in syngeneic mice. Our study provides evidence for a novel mechanism whereby tumors evade rejection by the immune system, and suggests the possibility that inhibiting IDO may be developed as an anti-cancer immunotherapeutic strategy.",
keywords = "Indoleamine 2,3-dioxygenase, T cell, Tumor",
author = "Maria Friberg and Ronald Jennings and Marwan Alsarraj and Sophie Dessureault and Alan Cantor and Martine Extermann and Mellor, {Andrew L.} and Munn, {David H.} and Antonia, {Scott J.}",
year = "2002",
month = "9",
day = "10",
doi = "10.1002/ijc.10645",
language = "English (US)",
volume = "101",
pages = "151--155",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection

AU - Friberg, Maria

AU - Jennings, Ronald

AU - Alsarraj, Marwan

AU - Dessureault, Sophie

AU - Cantor, Alan

AU - Extermann, Martine

AU - Mellor, Andrew L.

AU - Munn, David H.

AU - Antonia, Scott J.

PY - 2002/9/10

Y1 - 2002/9/10

N2 - The priming of an appropriate anti-tumor T cell response rarely results in the rejection of established tumors. The characteristics of tumors that allow them to evade a T cell-mediated rejection are unknown for many tumors. We report on evidence that the expression of the immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO) by mononuclear cells that invade tumors and tumor-draining lymph nodes, is I mechanism that may account for this observation. Lewis lung carcinoma (LLC) cells stimulated a more robust allogeneic T cell response in vitro in the presence of a competitive inhibitor of IDO, I-methyl tryptophan. When administered in vivo this inhibitor also resulted in delayed LLC tumor growth in syngeneic mice. Our study provides evidence for a novel mechanism whereby tumors evade rejection by the immune system, and suggests the possibility that inhibiting IDO may be developed as an anti-cancer immunotherapeutic strategy.

AB - The priming of an appropriate anti-tumor T cell response rarely results in the rejection of established tumors. The characteristics of tumors that allow them to evade a T cell-mediated rejection are unknown for many tumors. We report on evidence that the expression of the immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO) by mononuclear cells that invade tumors and tumor-draining lymph nodes, is I mechanism that may account for this observation. Lewis lung carcinoma (LLC) cells stimulated a more robust allogeneic T cell response in vitro in the presence of a competitive inhibitor of IDO, I-methyl tryptophan. When administered in vivo this inhibitor also resulted in delayed LLC tumor growth in syngeneic mice. Our study provides evidence for a novel mechanism whereby tumors evade rejection by the immune system, and suggests the possibility that inhibiting IDO may be developed as an anti-cancer immunotherapeutic strategy.

KW - Indoleamine 2,3-dioxygenase

KW - T cell

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0037056234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037056234&partnerID=8YFLogxK

U2 - 10.1002/ijc.10645

DO - 10.1002/ijc.10645

M3 - Article

C2 - 12209992

AN - SCOPUS:0037056234

VL - 101

SP - 151

EP - 155

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -